Skip to main content
Top
Published in: Abdominal Radiology 5/2009

01-09-2009

Radiologic findings following Y90 radioembolization for primary liver malignancies

Authors: Saad M. Ibrahim, Paul Nikolaidis, Frank H. Miller, Robert J. Lewandowski, Robert K. Ryu, Kent T. Sato, Sean Senthilnathan, Ahsun Riaz, Laura Kulik, Mary F. Mulcahy, Reed A. Omary, Riad Salem

Published in: Abdominal Radiology | Issue 5/2009

Login to get access

Abstract

A therapy gaining rapid clinical adoption involves radioembolization with the use of Yttrium-90 (90Y) microspheres. The 20–60 μm-sized microspheres are injected trans-arterially and flow to hepatic tumors given their preferential blood supply from the hepatic artery. Once they lodge in the arterioles, they impart a very intense local radiotherapeutic effect. Given the combined radiation and embolic effect, the imaging findings imparted by this mode of action differ significantly from other treatments. This work represents a comprehensive review of the imaging findings following radioembolization in patients with primary liver tumors. The report discusses imaging response, benign secondary effects, and complications. This should help educate the radiologist on imaging findings that should be expected following radioembolization and therefore aid in the proper image interpretation.
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
2.
go back to reference El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35:S72–S78PubMedCrossRef El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35:S72–S78PubMedCrossRef
3.
go back to reference El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576PubMedCrossRef El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576PubMedCrossRef
4.
5.
go back to reference Sato K, Lewandowski RJ, Bui JT, et al. (2006) Treatment of unresectable primary and metastatic liver cancer with Yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 29:522–529PubMedCrossRef Sato K, Lewandowski RJ, Bui JT, et al. (2006) Treatment of unresectable primary and metastatic liver cancer with Yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 29:522–529PubMedCrossRef
6.
go back to reference Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278PubMed Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278PubMed
7.
go back to reference Salem R, Thurston KG, Carr BI, et al. (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13:S223–S229PubMedCrossRef Salem R, Thurston KG, Carr BI, et al. (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13:S223–S229PubMedCrossRef
8.
go back to reference Dancey JE, Shepherd FA, Paul K, et al. (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41:1673–1681PubMed Dancey JE, Shepherd FA, Paul K, et al. (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41:1673–1681PubMed
9.
go back to reference Russell JL, Carden JL, Herron HL (1988) Dosimetry calculations for yttrium-90 used in the treatment of liver cancer. Endocurietherapy/Hyperthermia Oncol 4:171–186 Russell JL, Carden JL, Herron HL (1988) Dosimetry calculations for yttrium-90 used in the treatment of liver cancer. Endocurietherapy/Hyperthermia Oncol 4:171–186
10.
go back to reference Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 2: special topics. J Vasc Interv Radiol 17:1425–1439PubMed Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 2: special topics. J Vasc Interv Radiol 17:1425–1439PubMed
11.
go back to reference Kennedy A, Nag S, Salem R, et al. (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13–23PubMed Kennedy A, Nag S, Salem R, et al. (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13–23PubMed
12.
go back to reference Ibrahim SM, Lewandowski RJ, Sato KT, et al. (2008) Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 14:1664–1669PubMedCrossRef Ibrahim SM, Lewandowski RJ, Sato KT, et al. (2008) Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 14:1664–1669PubMedCrossRef
13.
go back to reference Covey AM, Brody LA, Maluccio MA, et al. (2002) Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 224:542–547PubMedCrossRef Covey AM, Brody LA, Maluccio MA, et al. (2002) Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 224:542–547PubMedCrossRef
14.
go back to reference Allen PJ, Stojadinovic A, Ben-Porat L, et al. (2002) The management of variant arterial anatomy during hepatic arterial infusion pump placement. Ann Surg Oncol 9:875–880PubMedCrossRef Allen PJ, Stojadinovic A, Ben-Porat L, et al. (2002) The management of variant arterial anatomy during hepatic arterial infusion pump placement. Ann Surg Oncol 9:875–880PubMedCrossRef
15.
go back to reference Carr BI (2002) Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterology 49:79–86PubMed Carr BI (2002) Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterology 49:79–86PubMed
16.
go back to reference Chun HJ, Byun JY, Yoo SS, Choi BG (2003) Added benefit of thoracic aortography after transarterial embolization in patients with hemoptysis. AJR 180:1577–1581PubMed Chun HJ, Byun JY, Yoo SS, Choi BG (2003) Added benefit of thoracic aortography after transarterial embolization in patients with hemoptysis. AJR 180:1577–1581PubMed
17.
go back to reference Arora R, Soulen MC, Haskal ZJ (1999) Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol 10:1351–1356PubMedCrossRef Arora R, Soulen MC, Haskal ZJ (1999) Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol 10:1351–1356PubMedCrossRef
18.
go back to reference Ueno K, Miyazono N, Inoue H, et al. (1995) Embolization of the hepatic falciform artery to prevent supraumbilical skin rash during transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol 18:183–185PubMedCrossRef Ueno K, Miyazono N, Inoue H, et al. (1995) Embolization of the hepatic falciform artery to prevent supraumbilical skin rash during transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol 18:183–185PubMedCrossRef
19.
go back to reference Inaba Y, Arai Y, Matsueda K, et al. (2001) Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 12:957–963PubMedCrossRef Inaba Y, Arai Y, Matsueda K, et al. (2001) Right gastric artery embolization to prevent acute gastric mucosal lesions in patients undergoing repeat hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 12:957–963PubMedCrossRef
20.
go back to reference Chung JW, Park JH, Han JK, et al. (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33–40PubMed Chung JW, Park JH, Han JK, et al. (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33–40PubMed
21.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef
22.
go back to reference Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR 188:768–775PubMedCrossRef Keppke AL, Salem R, Reddy D, et al. (2007) Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR 188:768–775PubMedCrossRef
23.
go back to reference Atassi B, Bangash AK, Bahrani A, et al. (2008) Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 28:81–99PubMedCrossRef Atassi B, Bangash AK, Bahrani A, et al. (2008) Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics 28:81–99PubMedCrossRef
24.
go back to reference Kulik LM, Atassi B, van Holsbeeck L, et al. (2006) Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572–586PubMedCrossRef Kulik LM, Atassi B, van Holsbeeck L, et al. (2006) Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572–586PubMedCrossRef
25.
go back to reference Salem R, Lewandowski RJ, Atassi B, et al. (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627–1639PubMed Salem R, Lewandowski RJ, Atassi B, et al. (2005) Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627–1639PubMed
26.
go back to reference Sangro B, Bilbao JI, Boan J, et al. (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66:792–800PubMed Sangro B, Bilbao JI, Boan J, et al. (2006) Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 66:792–800PubMed
27.
go back to reference Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef
28.
go back to reference Kulik LM, Carr BI, Mulcahy MF, et al. (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81PubMedCrossRef Kulik LM, Carr BI, Mulcahy MF, et al. (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81PubMedCrossRef
29.
go back to reference Liapi E, Geschwind JF, Vossen JA, et al. (2008) Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR 190:67–73PubMedCrossRef Liapi E, Geschwind JF, Vossen JA, et al. (2008) Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR 190:67–73PubMedCrossRef
30.
go back to reference Deng J, Miller FH, Rhee TK, et al. (2006) Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17:1195–1200PubMedCrossRef Deng J, Miller FH, Rhee TK, et al. (2006) Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17:1195–1200PubMedCrossRef
31.
go back to reference Deng J, Virmani S, Young J, et al. (2008) Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits. J Magn Reson Imaging 27:1069–1076PubMedCrossRef Deng J, Virmani S, Young J, et al. (2008) Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits. J Magn Reson Imaging 27:1069–1076PubMedCrossRef
32.
go back to reference Kamel IR, Bluemke DA, Ramsey D, et al. (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR 181:708–710PubMed Kamel IR, Bluemke DA, Ramsey D, et al. (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR 181:708–710PubMed
33.
go back to reference Sarikaya I, Bloomston M, Povoski SP, et al. (2007) FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 5:64PubMedCrossRef Sarikaya I, Bloomston M, Povoski SP, et al. (2007) FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 5:64PubMedCrossRef
34.
go back to reference Miller FH, Keppke AL, Reddy D, et al. (2007) Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR 188:776–783PubMedCrossRef Miller FH, Keppke AL, Reddy D, et al. (2007) Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR 188:776–783PubMedCrossRef
35.
go back to reference Kennedy AS, Coldwell D, Nutting C, et al. (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412–425PubMed Kennedy AS, Coldwell D, Nutting C, et al. (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412–425PubMed
36.
go back to reference Sato KT, Lewandowski RJ, Mulcahy MF, et al. (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres–safety, efficacy, and survival. Radiology 247:507–515PubMedCrossRef Sato KT, Lewandowski RJ, Mulcahy MF, et al. (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres–safety, efficacy, and survival. Radiology 247:507–515PubMedCrossRef
37.
go back to reference Khan SA, Davidson BR, Goldin R, et al. (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 Suppl 6:VI1–9PubMedCrossRef Khan SA, Davidson BR, Goldin R, et al. (2002) Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 Suppl 6:VI1–9PubMedCrossRef
38.
go back to reference Kulik LM, Mulcahy MF, Hunter RD, et al. (2005) Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl 11:1127–1131PubMedCrossRef Kulik LM, Mulcahy MF, Hunter RD, et al. (2005) Use of yttrium-90 microspheres (TheraSphere) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: a case report. Liver Transpl 11:1127–1131PubMedCrossRef
39.
go back to reference Lewandowski R, Salem R, Thurston K, et al. (2004) Radiation segmentectomy of unresectable of liver carcinoma using selective infusion of intraarterial Yttrium-90 theraSphere. Radiological Society of North America, Chicago Lewandowski R, Salem R, Thurston K, et al. (2004) Radiation segmentectomy of unresectable of liver carcinoma using selective infusion of intraarterial Yttrium-90 theraSphere. Radiological Society of North America, Chicago
40.
go back to reference Rhee TK, Omary RA, Gates V, et al. (2005) The effect of catheter-directed CT angiography on Yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 16:1085–1091PubMed Rhee TK, Omary RA, Gates V, et al. (2005) The effect of catheter-directed CT angiography on Yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 16:1085–1091PubMed
41.
go back to reference Jakobs TF, Saleem S, Atassi B, et al. (2008) Fibrosis, portal hypertension, hepatic volume changes induced by intra-arterial radiotherapy with (90)Yttrium microspheres. Dig Dis Sci 53(9):2556–2563PubMedCrossRef Jakobs TF, Saleem S, Atassi B, et al. (2008) Fibrosis, portal hypertension, hepatic volume changes induced by intra-arterial radiotherapy with (90)Yttrium microspheres. Dig Dis Sci 53(9):2556–2563PubMedCrossRef
42.
go back to reference Cherqui D, Palazzo L, Piedbois P, et al. (1994) Common bile duct stricture as a late complication of upper abdominal radiotherapy. J Hepatol 20:693–697PubMedCrossRef Cherqui D, Palazzo L, Piedbois P, et al. (1994) Common bile duct stricture as a late complication of upper abdominal radiotherapy. J Hepatol 20:693–697PubMedCrossRef
43.
go back to reference Nakakubo Y, Kondo S, Katoh H, et al. (2000) Biliary stricture as a possible late complication of radiation therapy. Hepatogastroenterology 47:1531–1532PubMed Nakakubo Y, Kondo S, Katoh H, et al. (2000) Biliary stricture as a possible late complication of radiation therapy. Hepatogastroenterology 47:1531–1532PubMed
44.
go back to reference Liu DM, Salem R, Bui JT, et al. (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935PubMed Liu DM, Salem R, Bui JT, et al. (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935PubMed
45.
go back to reference Sakamoto I, Iwanaga S, Nagaoki K, et al. (2003) Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR 181:79–87PubMed Sakamoto I, Iwanaga S, Nagaoki K, et al. (2003) Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR 181:79–87PubMed
46.
go back to reference Atassi B, Bangash AK, Lewandowski RJ, et al. (2008) Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol 19:691–697PubMedCrossRef Atassi B, Bangash AK, Lewandowski RJ, et al. (2008) Biliary sequelae following radioembolization with yttrium-90 microspheres. J Vasc Interv Radiol 19:691–697PubMedCrossRef
47.
go back to reference Murthy R, Brown DB, Salem R, et al. (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553–561 quiz 62PubMedCrossRef Murthy R, Brown DB, Salem R, et al. (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553–561 quiz 62PubMedCrossRef
48.
go back to reference Lewandowski RJ, Sato KT, Atassi B, et al. (2007) Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30:571–592PubMedCrossRef Lewandowski RJ, Sato KT, Atassi B, et al. (2007) Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30:571–592PubMedCrossRef
49.
go back to reference Salem R, Lewandowski RJ, Sato KT, et al. (2007) Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 10:12–29PubMedCrossRef Salem R, Lewandowski RJ, Sato KT, et al. (2007) Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 10:12–29PubMedCrossRef
50.
go back to reference Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200–208PubMed Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200–208PubMed
51.
go back to reference Lawrence TS, Robertson JM, Anscher MS, et al. (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237–1248PubMed Lawrence TS, Robertson JM, Anscher MS, et al. (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237–1248PubMed
52.
go back to reference Sangro B, Gil-Alzugaray B, Rodriguez J, et al. (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538–1546PubMedCrossRef Sangro B, Gil-Alzugaray B, Rodriguez J, et al. (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538–1546PubMedCrossRef
53.
go back to reference Young JY, Rhee TK, Atassi B, et al. (2007) Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 18:1375–1382PubMedCrossRef Young JY, Rhee TK, Atassi B, et al. (2007) Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 18:1375–1382PubMedCrossRef
54.
go back to reference Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38(Suppl 1):S136–S149PubMedCrossRef Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38(Suppl 1):S136–S149PubMedCrossRef
55.
go back to reference Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442PubMedCrossRef Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442PubMedCrossRef
Metadata
Title
Radiologic findings following Y90 radioembolization for primary liver malignancies
Authors
Saad M. Ibrahim
Paul Nikolaidis
Frank H. Miller
Robert J. Lewandowski
Robert K. Ryu
Kent T. Sato
Sean Senthilnathan
Ahsun Riaz
Laura Kulik
Mary F. Mulcahy
Reed A. Omary
Riad Salem
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 5/2009
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-008-9454-y

Other articles of this Issue 5/2009

Abdominal Radiology 5/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.